independence blue cross glp 1 coverage Why we are changing of GLP-1 drugs for weight loss Getting health care right |

Our customization process aims to address the specific physiological deficits each athlete presents with, rather than applying a standardized protocol

Weakness that you blame on the calorie deficit

This dual-peptide formulation combines CJC-1295 (No DAC) (5 mg) with Ipamorelin (5 mg), a selective ghrelin receptor agonist

People who are obese, based on their height and weight, have an amount of fat on their bodies representing a BMI of 30 or higher

GLP-1 drugs lead to weight loss by slowing the movement of food in the stomach and by interacting with receptors in the brain to promote a feeling of fullness

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes . Journal of the American Heart Association , 2024